MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
MindWalk Holdings Corp. (NASDAQ: HYFT) reported fiscal 2026 results for the year ended April 30, 2026. Revenue rose 46% to $15.6 million and gross margin increased to 59%. Net loss narrowed to $13.9 million from $30.2 million. The company said it completed a pivot to BioIntelligence infrastructure, divested a Netherlands unit, and launched ReefIQ in June 2026.
How this was made
The 30-second read
Why it matters
Traders can reassess HYFT’s trajectory based on the combination of (1) full-year financial improvement, (2) first recurring platform revenue claims, (3) ReefIQ commercial launch, and (4) a share repurchase authorization after regaining Nasdaq compliance.
Market read
The article is a primary financial results release with specific margin and loss improvements plus early recurring revenue and product launch milestones, which can drive near-term re-rating for a small-cap platform story.
What to watch
The article highlights non-cash amortization/impairment non-recurrence driving expense comparisons, and it does not quantify cash burn or contract economics (ACV, renewal rates), which are critical for validating the recurring revenue thesis.
Background
MindWalk completed a corporate transformation (from ImmunoPrecise Antibodies) and is positioning HYFT Technology as the biological context layer (ReefIQ) feeding LensAI recurring enterprise arrangements.
Ticker impact
MindWalk reports fiscal 2026 revenue up 46% to $15.6M, gross margin to 59%, and net loss narrowing, alongside a pivot to BioIntelligence infrastructure.
Moderately positive bias for HYFT, with upside skew if investors focus on recurring LensAI contracts and ReefIQ launch; downside risk if growth is viewed as still small-scale versus cash burn.
The article provides concrete financial datapoints (revenue, margins, net loss) plus specific business milestones (first recurring LensAI agreements, ReefIQ commercial launch, share repurchase authorization). However, it lacks guidance, backlog size, and cash-flow detail beyond cash balance, limiting conviction on forward trajectory.
Market effects
Supports the broader life-sciences AI narrative that data/context layers can drive recurring enterprise value, potentially influencing sentiment toward similar bio-native AI infrastructure plays.
Limited direct regional read-through; primarily US-listed small-cap biotech-AI sentiment.
Low global macro relevance; more of a niche read-through to AI drug discovery tooling and platform monetization models.
Counterpoint
The revenue base is still small ($15.6M) and operating expenses rose in key areas (R&D, sales and marketing), so margin expansion may not persist as growth scales.
Key entities
- companyMindWalk Holdings Corp.
NASDAQ-listed Bio-Native AI company reporting fiscal 2026 results and detailing its pivot to BioIntelligence infrastructure.
- productReefIQ
Commercially launched biological context layer in June 2026 powered by HYFT Technology.
- platformLensAI
Enterprise AI offering described as having signed first contracted, recurring agreements during fiscal 2026.
- transaction_partyAVS Bio
Buyer of MindWalk’s Netherlands subsidiary in a disposal transaction announced in August 2025.
